About Yoshindo

About company

Toward the research and development required for pharmaceuticals in the future, Yoshindo is currently working on multiple biopharmaceutical businesses. One is contract manufacturing of biopharmaceuticals. This led to the start of an advanced approach to biopharmaceuticals that is unusual for a generic manufacturer. In addition, YL Biologics, a joint venture established with Rupin Limited of India, has succeeded in the global development of biosimilars for the treatment of rheumatoid arthritis, Emblem, and YL Biologics is in charge of manufacturing and sales in Japan.